Adalimumab: a new modality for Behçet's disease?

Authors:
  • TMT Missotten
    T Missotten
  • PDP L A van Daele
    P L A van Daele
  • AJA Jamnitski
    A Jamnitski
  • GBG S Baarsma
    G S Baarsma
  • PHP M van Hagen
    P M van Hagen

Abstract
These patients were treated in the past with infliximab.9 Indications for anti-TNFα treatment were uveitis (patients 2 and 4), CNS disease (patients 3 and 5), colitis (patient 6) and severe oral ulcers and arthritis (patient 1), and are further presented in table 1. Symptoms were scored retrospectively since no official scoring system such as the Behcet’s Disease Current Activity Form (BDCAF) was available at the start of anti-TNFα treatment in our centre.

This publication has 9 references indexed in Scilit: